# A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia

> **NCT01808092** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 969 (actual)

## Conditions studied

- Nosocomial Pneumonia (NP)
- Ventilator-associated Pneumonia (VAP)

## Interventions

- **DRUG:** ceftazidim-avibactam (CAZ-AVI, experimental product)
- **DRUG:** meropenem (active comparator)

## Key facts

- **NCT ID:** NCT01808092
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 969 (ACTUAL)
- **Last updated:** 2017-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808092, "A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01808092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*